HEALTHY U CHIP

PRIOR AUTHORIZATION REQUEST FORM

PHENYLBUTYRATES

Buphenyl®, Pheburane®, Ravicti®

For authorization, please answer each question and fax this form PLUS chart notes back to the Healthy U CHIP Prior Authorization Department at 385-425-4052.

Failure to submit clinical documentation to support this request will result in a dismissal of the request.

If you have prior authorization questions, please call for assistance: 385-425-5094

Disclaimer: Prior Authorization request forms are subject to change in accordance with Federal and State notice requirements.

Date:	Member Name:	ID#:
DOB:	Gender:	Physician:
Office Phone:	Office Fax:	Office Contact:
Height/Weight:		

Member must try formulary preferred drugs before a request for a non-preferred drug may be considered. If treatment with preferred products has not been successful, you must submit which preferred products have been tried, dates of treatment, and reason for failure. Reasons for failure must meet the Health Plan medical necessity criteria.

Preferred: ☐ sodium phenylbutyrate powder, ☐ sodium phenylbutyrate tablets
Preferred after trial and failure of one of sodium phenylbutyrate powder or tablets: ☐ Pheburane® (sodium phenylbutyrate)
Non-preferred: ☐ Ravicti® (glycerol phenylbutyrate)

Dosing/Frequency:_____

If the request is for reauthorization, proceed to reauthorization section

Questions	Yes	No	Comments/Notes
1. Does the member have a diagnosis of urea cycle disorder requiring chronic management that is confirmed by enzymatic, biochemical or genetic testing?	☐	☐	**Please provide documentation**
2. Does documentation show that the member's condition has not been managed adequately by dietary protein restriction and/or amino acid supplementation alone?	☐	☐	**Please provide documentation**
3. Has a nutritional consultation been performed to assess diet?	☐	☐	**Please provide documentation**
4. Will phenylbutyrate be used in combination with a dietary protein restriction?	☐	☐	
5. Does the requesting provider have experience managing urea cycle disorder?	☐	☐	
6. Is the request for Ravicti®? **Please note: For Ravicti®, treatment failure for "bad taste" or "taste aversion" will only be allowed in members ≤11 years old.**	☐	☐	
7. Has the member tried and failed or have a contraindication to sodium phenylbutyrate? (Contraindications may include comorbid conditions which limit sodium intake, such as heart failure, renal impairment, hypertension and edema)	☐	☐	**Please provide documentation**

REAUTHORIZATION			
1. Is the request for reauthorization of therapy?	☐	☐	
2. Does updated documentation show a continued medical necessity and clinical efficacy of therapy?	☐	☐	**Please provide documentation**
What medications and/or treatment modalities have been tried in the past for this condition? Please document name of treatment, reason for failure, treatment dates, etc.			
Additional information:			
Physician's Signature:			

**** Failure to submit clinical documentation to support this request will result in a dismissal of the request.****

Policy: PHARM-CHIP-058
Origination Date: 07/01/2024
Reviewed/Revised Date:
Next Review Date:
Current Effective Date: 07/01/2024